Krystal Biotech, Inc.

Krystal Biotech is a commercial-stage biotechnology company developing genetic medicines for rare genetic and dermatological disorders. The company's lead product, VYJUVEK (beremagene geperpavec-svdt), was approved by the FDA and is marketed for dystrophic epidermolysis bullosa (DEB), a severe blistering disorder caused by mutations in the COL7A1 gene. This represents the company's primary revenue stream since its commercial launch.

The pipeline includes multiple programs in clinical development targeting rare indications with limited treatment options. KB803 addresses ocular complications associated with DEB, while KB801 is in development for neurotrophic keratitis. Early-stage programs include KB407 for cystic fibrosis, KB111 for Hailey-Hailey disease, and KB408 for Alpha-1 antitrypsin deficiency, among others. The company also has development programs in oncology and aesthetic dermatology.

Krystal Biotech operates from its headquarters in Pittsburgh, Pennsylvania, with approximately 295 full-time employees. The company was incorporated in 2016 and is listed on the Nasdaq. Its operations are concentrated in the United States market, where it manufactures and distributes its approved therapeutic.